Dr. R. Wayne Davies: Chief Executive Officer Dr. Davies has a unique combination of international level scientific achievement with extensive business experience. He has six years of direct experience as Chief Executive Officer of two biotechnology companies, Neuropa Ltd. (a spin-out company of the University of Glasgow) and UmanGenomics AB of Umeå, Sweden. In these roles he had hands-on experience of biotechnology company management, Board membership, multi-round fundraising from venture capital and local Angel sources and interaction with major pharmaceutical companies. Previously, he was Vice-President for Science of Canada’s then flagship biotechnology company, Allelix Biopharmaceuticals, where he managed a staff of 70 scientists and played a leading role in establishing co-development work with pharmaceutical companies. Wayne is also an expert in genetics, molecular biology and neuroscience, with many publications in major scientific journals. He has been Professor of Biotechnology at the University of Glasgow since 1989, and led the team which started the commercial development of the science underlying BrainWave. He brings mammalian molecular neuroscience expertise and relevant commercial experience to the company.
Dr. J. Douglas Armstrong: Chief Scientific and Operating Officer Dr. Armstrong is an expert in Drosophila genetics and molecular biology, computing and informatics and is active in a number of business networks in the pharmaceutical sector. Douglas was part of the academic team that first developed the BrainWave assay, and has since published important work in Drosophila behaviour genetics and nervous system molecular network analysis. He provides core bioinformatics, synthetic biology, Drosophila neurogenetics and behaviour expertise to the company. He is also a Reader at the School of Informatics at the University of Edinburgh and Assistant Professor (Adjunct) of Biochemistry and Cell Biology at Rice University.
Matt B Mahoney: Director of Business Development - North American Region Matt B. Mahoney, Director of Business Development - North American Region. Matt B. Mahoney has been working closely with Drosophila for over ten years. After studying genetics at the University of California, Berkeley, Matt joined the Alzheimer's disease team at Exelixis Inc., where he ran forward genetic screens for various clients. Subsequently, he was recruited to EnVivo Pharmaceuticals, where he helped to optimize and run their Drosophila behavioral screening platform and was integral to the identification of multiple treatment candidates for neurodegenerative diseases. This group spun off into a separate company, Vitruvean, LLC, where Matt was responsible for Drosophila-based drug screening, marketing and business development. This invaluable experience is now focused on the development of Brainwave-Discovery's business in the USA and Canada. Customers in this region should contact Matt directly on m.mahoney@brainwave-discovery.com

Copyright Brainwave Discovery Ltd. 2008,2009.

Home